This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists. In this study, patients with essential hypertension and at least one additional risk factor will be included. Patients may take any antihypertensive treatment which is approved for cardiovascular protection including Micardis 80 mg / Micardis Plus. Patients will be followed over one year in four visits from baseline to endpoint with an additional visit before and after the month of Ramadan.
Purpose:
Study Type
OBSERVATIONAL
Enrollment
1,674
Achievement of the JNC 7 Treatment Goals (BP <140/90 mmHg) at Week 52
The proportion of patients enrolled in the study who achieve the JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) treatment goals (blood pressure (BP) \<140/90 mmHg) in a primary-care setting at week 52. This variable was derived from the mean sitting blood pressure assessed by the investigators at week 52. To achieve JNC 7 treatment goals, the subject had to satisfy both blood pressure criteria - systolic blood pressure below 140 mm Hg and diastolic blood pressure below 90 mm Hg.
Time frame: Up to 52 weeks
Achieving JNC 7 Treatment Goals After Ramadan
The proportion of patients enrolled in the study who achieve the JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) treatment goals (blood pressure (BP) \<140/90 mmHg) in a primary-care setting after Ramadan. This variable was derived from the mean sitting blood pressure assessed by the investigators after Ramadan. To achieve JNC 7 treatment goals, the subject had to satisfy both blood pressure criteria - systolic blood pressure below 140 mm Hg and diastolic blood pressure below 90 mm Hg.
Time frame: 1 month
Cardiovascular Events
Percentage of participants who experienced a major cardiovascular (CV) event
Time frame: Up to 52 weeks
The Overall Assessment of Treatment by Patients at 52 Weeks
The overall assessment of treatment by patients at 52 weeks. Assessed using a verbal rating scale with 5 categories: Outstanding, very satisfactory, satisfactory, marginal and not satisfactory.
Time frame: Up to 52 weeks
The Overall Assessment of Treatment by Physicians at 52 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site 106
Algiers, Algeria
Boehringer Ingelheim Investigational Site 107
Algiers, Algeria
Boehringer Ingelheim Investigational Site 108
Algiers, Algeria
Boehringer Ingelheim Investigational Site 109
Algiers, Algeria
Boehringer Ingelheim Investigational Site 110
Algiers, Algeria
Boehringer Ingelheim Investigational Site 111
Algiers, Algeria
Boehringer Ingelheim Investigational Site 112
Algiers, Algeria
Boehringer Ingelheim Investigational Site 113
Algiers, Algeria
Boehringer Ingelheim Investigational Site 114
Algiers, Algeria
Boehringer Ingelheim Investigational Site 115
Algiers, Algeria
...and 122 more locations
The overall assessment of treatment by physicians at 52 weeks. Assessed using a verbal rating scale with 5 categories: Outstanding, very satisfactory, satisfactory, marginal and not satisfactory.
Time frame: Up to 52 weeks
Compliance of Patients up to 10 Days Before Ramadan
Compliance of patients up to 10 days before ramadan (treated by internists and cardiologists as primary physician). Subjects were asked how often they have not taken their medicine and were given five possible choices from "none of the time" to "all of the time".
Time frame: 10 days before Ramadan
Compliance of Patients up to 10 Days After Ramadan
Compliance of patients up to 10 days after Ramadan (treated by internists and cardiologists as primary physician). Subjects were asked how often they have not taken their medicine and were given five possible choices from "none of the time" to "all of the time".
Time frame: 10 days after Ramadan
Compliance of Patients During the Whole Study Duration (52 Weeks)
Compliance of patients during the whole study duration (treated by internists and cardiologists as primary physician). Subjects were asked how often they have not taken their medicine and were given five possible choices from "none of the time" to "all of the time".
Time frame: Up to 52 weeks
Achievement of the JNC 7 Treatment Goals During the Whole Study Duration (Treated by Internists and Cardiologists as Primary Physician)
Proportion of patients who achieved the JNC 7 treatment goals during the whole study duration (treated by internists and cardiologists as primary physician)
Time frame: Up to 52 weeks
The Difference in Systolic Blood Pressure Before and After the Month of Ramadan
Change from baseline in systolic blood pressure before and after the month of Ramadan
Time frame: Baseline, 10 days before Ramadan, 10 days after Ramadan and 52 weeks
The Difference in Diastolic Blood Pressure Before and After the Month of Ramadan
Change from baseline in diastolic blood pressure before and after the month of Ramadan
Time frame: Baseline, 10 days before Ramadan, 10 days after Ramadan and 52 weeks
The Percentage of Patients Achieving JNC 7 Treatment Goals at the End of the 1 Year Treatment Duration
The proportion of patients enrolled in the study who achieve the JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) treatment goals (blood pressure (BP) \<140/90 mmHg) in a primary-care setting at the end of the 1 year treatment duration. This variable was derived from the mean sitting blood pressure assessed by the investigators at the end of the 1 year treatment duration. To achieve JNC 7 treatment goals, the subject had to satisfy both blood pressure criteria - systolic blood pressure below 140 mm Hg and diastolic blood pressure below 90 mm Hg. At this timepoint, a diagnosis of diabetes mellitus and/or kidney disease was also taken into account. Subjects with either of the mentioned conditions had to have systolic blood pressure lower than 130 mm Hg and diastolic blood pressure below 80 mm Hg to satisfy JNC 7 treatment goals.
Time frame: Up to 52 weeks
Adverse Events Under Angiotensin II (Type 1) Receptor Blockers (ARBs) Treatment When Given in Combination With Calcium-Channel Blockers (CCBs)
Number of participants with adverse events in participants receiving Angiotensin II (Type 1) Receptor Blockers (ARBs) when given in combination with Calcium-Channel Blockers (CCBs) during the whole study duration.
Time frame: Up to 52 weeks